Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

@article{Coles2008AlemtuzumabVI,
  title={Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.},
  author={Alasdair John Coles and D. Alastair S. Compston and Krzysztof W. Selmaj and Stephen L. Lake and Susan Moran and David H. Margolin and Kim Norris and Prabhat K Tandon},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 17},
  pages={1786-801}
}
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive either subcutaneous interferon beta-1a (at a dose of 44… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 310 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

De - 31 . velopment of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases : role of conditioning regimen used

  • JL Jones, S Thompson, AL Cox
  • Blood
  • 2007

Idiopath - ic thrombocytopenic purpura in patients with multiple sclerosis

  • SH Otton, DL Turner, R Frewin, SA Johnson
  • Mult Scler
  • 2006

Prevalence of im - 27 . mune thrombocytopenia : analyses of administrative data

  • E Munteis, N Segura, J Martinez, E Cuadrado, A Galvez, J Roquer
  • J Thromb Haemost
  • 2006

Prevalence of other autoimmune diseases in patients with multiple sclerosis

  • H Granier, S Bellard, X Nicolas, JP Laborde, F Talarmin
  • Mult Scler
  • 2005

Fatal thrombocy - 30 . topaenia temporally related to the administration of alemtuzumab ( MabCampath ) for refractory CLL despite early discontinuation of therapy

  • Y Loh, Y Oyama, L Statkute
  • Hematology
  • 2004

Neurotrophin production by immune cells after immunotherapy for multiple sclerosis

  • ston DAS, AJ Coles
  • J Neuroimmunol 2004;154:212
  • 2004

Similar Papers

Loading similar papers…